SC 13G

Name of reporting persons.

Boxer Capital, LLC

Check the appropriate box if a member of a group. (See instructions)

(a) ☐ (b) ☒

SEC use only.

Citizenship or place of organization.

Delaware

0001193125-20-259677.txt : 20200930 0001193125-20-259677.hdr.sgml : 20200930 20200930163356 ACCESSION NUMBER: 0001193125-20-259677 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20200930 DATE AS OF CHANGE: 20200930 GROUP MEMBERS: AARON I. DAVIS GROUP MEMBERS: BOXER ASSET MANAGEMENT INC. GROUP MEMBERS: JOE LEWIS GROUP MEMBERS: MVA INVESTORS, LLC SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: PMV Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001699382 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 463218129 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-91714 FILM NUMBER: 201212601 BUSINESS ADDRESS: STREET 1: 8 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 642-6664 MAIL ADDRESS: STREET 1: 8 CLARKE DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Boxer Capital, LLC CENTRAL INDEX KEY: 0001465837 IRS NUMBER: 203828456 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 320 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: (858) 400-3112 MAIL ADDRESS: STREET 1: 11682 EL CAMINO REAL STREET 2: SUITE 320 CITY: SAN DIEGO STATE: CA ZIP: 92130 SC 13G 1 d71324dsc13g.htm SC 13G SC 13G

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. )*

PMV Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value per share

(Title of Class of Securities)

69353Y103

(CUSIP Number)

September 25, 2020

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☒ Rule 13d-1(c)

☐ Rule 13d-1(d)

*	The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 69353Y103

*	Based on 44,764,060 shares of Common Stock outstanding immediately following the completion of the Issuer’s initial public offering, as set forth in the Issuer’s prospectus supplement filed with the US Securities and Exchange Commission on September 25, 2020.

CUSIP No. 69353Y103

*	Based on 44,764,060 shares of Common Stock outstanding immediately following the completion of the Issuer’s initial public offering, as set forth in the Issuer’s prospectus supplement filed with the US Securities and Exchange Commission on September 25, 2020.

CUSIP No. 69353Y103

*	Based on 44,764,060 shares of Common Stock outstanding immediately following the completion of the Issuer’s initial public offering, as set forth in the Issuer’s prospectus supplement filed with the US Securities and Exchange Commission on September 25, 2020.

CUSIP No. 69353Y103

*	Based on 44,764,060 shares of Common Stock outstanding immediately following the completion of the Issuer’s initial public offering, as set forth in the Issuer’s prospectus supplement filed with the US Securities and Exchange Commission on September 25, 2020.

CUSIP No. 69353Y103

*	Based on 44,764,060 shares of Common Stock outstanding immediately following the completion of the Issuer’s initial public offering, as set forth in the Issuer’s prospectus supplement filed with the US Securities and Exchange Commission on September 25, 2020.

Item 1(a).

Name of Issuer:

PMV Pharmaceuticals Inc. (the “Issuer”)

Item 1(b).

Address of Issuer’s Principal Executive Offices:

8 Clarke Drive, Suite 3

Cranbury, NJ 08512

Item 2(a).

Name of Person Filing:

This Schedule 13G is jointly filed by Boxer Capital, LLC (“Boxer Capital”), Boxer Asset Management Inc. (“Boxer Management”), Joe Lewis, MVA Investors, LLC (“MVA Investors”) and Aaron I. Davis (collectively, the “Reporting Persons”). Boxer Management is the managing member and majority owner of Boxer Capital. Joe Lewis is the sole indirect beneficial owner of and controls Boxer Management. MVA Investors is the independent, personal investment vehicle of certain employees of Boxer Capital. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors.

Item 2(b).

Address of Principal Business Office, or, if none, Residence:

The principal business address of Boxer Capital, MVA Investors and Aaron I. Davis is: 11682 El Camino Real, Suite 320, San Diego, CA 92130. The principal business address of Boxer Management and Joe Lewis is: Cay House, EP Taylor Drive N7776, Lyford Cay, New Providence, Bahamas.

Item 2(c).

Citizenship:

Boxer Capital and MVA Investors are limited liability companies organized under the laws of Delaware. Boxer Management is a corporation organized under the laws of the Bahamas. Joe Lewis is a citizen of the United Kingdom. Aaron I. Davis is a citizen of the United States of America.

Item 2(d).

Title of Class of Securities:

Common Stock, $0.00001 par value per share

Item 2(e).

CUSIP Number:

69353Y103

Item 3.

If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

Not applicable.

Item 4.

Ownership.

(a)

Amount beneficially owned:

Boxer, Boxer Management and Joe Lewis beneficially own 2,268,236 shares of Common Stock. MVA Investors and Aaron I. Davis beneficially own 60,837 shares of Common Stock. The Reporting Persons beneficially own, in the aggregate, 2,329,073 shares of Common Stock.

(b)

Percent of class:

The number of shares of Common Stock beneficially owned by the Reporting Persons in the aggregate represent 5.2% of the Issuer’s outstanding shares of Common Stock (based on 44,764,060 shares of Common Stock outstanding immediately following the completion of the Issuer’s initial public offering, as set forth in the Issuer’s prospectus supplement filed with the US Securities and Exchange Commission on September 25, 2020).

(c)

Number of shares as to which such person has:

(i)

Sole power to vote or to direct the vote:

None of the Reporting Persons has sole power to vote or to direct the vote of any shares of Common Stock.

(ii)

Shared power to vote or to direct the vote:

Boxer Capital, Boxer Management and Joe Lewis have shared power to vote or to direct the vote of the 2,268,236 shares of Common Stock they beneficially own. MVA Investors and Aaron I. Davis have shared power to vote or to direct the vote of the 60,837 shares of Common Stock they beneficially own.

(iii)

Sole power to dispose or to direct the disposition of:

None of the Reporting Persons has sole power to dispose or to direct the disposition of any shares of Common Stock.

(iv)

Shared power to dispose or to direct the disposition of:

Boxer Capital, Boxer Management and Joe Lewis have shared power to dispose or to direct the disposition of the 2,268,236 shares of Common Stock they beneficially own. MVA Investors and Aaron I. Davis have shared power to dispose or to direct the disposition of the 60,837 shares of Common Stock they beneficially own.

Item 5.

Ownership of Five Percent or Less of a Class.

Not applicable.

Item 6.

Ownership of More than Five Percent on Behalf of Another Person.

Only Boxer Capital has the right to receive dividends and the proceeds from the sale of the Common Stock held by Boxer Capital. Only MVA Investors has the right to receive dividends and the proceeds from the sale of the Common Stock held by MVA Investors.

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

Item 8.

Identification and Classification of Members of the Group.

Not applicable.

Item 9.

Notice of Dissolution of Group.

Not applicable.

Item 10.

Certification.

(c) By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Exhibits

Joint Filing Agreement, dated September 30, 2020, among the Reporting Persons.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 30, 2020


BOXER CAPITAL, LLC

By:		/s/ Aaron I. Davis
Name:		Aaron I. Davis
Title:		Authorized Signatory

BOXER ASSET MANAGEMENT INC.

By:		/s/ Jason Callender
Name:		Jason Callender
Title:		Director

JOSEPH C. LEWIS

/s/ Joseph C. Lewis
Joseph C. Lewis, Individually

MVA INVESTORS, LLC

By:		/s/ Aaron I. Davis
Name:		Aaron I. Davis
Title:		Authorized Signatory

AARON I. DAVIS

By:		/s/ Aaron I. Davis
		Aaron I. Davis, Individually

EX-99.1 2 d71324dex991.htm EX-99.1 EX-99.1

JOINT FILING AGREEMENT

The undersigned hereby agree that the Statement on Schedule 13G with respect to the common stock of PMV Pharmaceuticals, Inc., $0.00001 par value per share, is, and any amendments thereto executed by each of us shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, and that this Agreement shall be included as an Exhibit to the Schedule 13G and each such amendment. Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of September 30, 2020.


BOXER CAPITAL, LLC

By:		/s/ Aaron I. Davis
Name:		Aaron I. Davis
Title:		Authorized Signatory

BOXER ASSET MANAGEMENT INC.

By:		/s/ Jason Callender
Name:		Jason Callender
Title:		Director

JOSEPH C. LEWIS

/s/ Joseph C. Lewis
Joseph C. Lewis, Individually

MVA INVESTORS, LLC

By:		/s/ Aaron I. Davis
Name:		Aaron I. Davis
Title:		Authorized Signatory

AARON I. DAVIS

By:		/s/ Aaron I. Davis
		Aaron I. Davis, Individually